Acute kidney injury

Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022

Retrieved on: 
Tuesday, June 14, 2022
SAMI, Renal replacement therapy, Biomarker, Lipopolysaccharide, EDT, Classification, Decision-making, Septic shock, News, RRT, Toronto Stock Exchange, Acute kidney injury, FDA, Health Canada, Patient, GLOBE, PMX, Risk, U.S. FDA, Sepsis, Federal Food, Drug, and Cosmetic Act, JAMA, TSX, EBP, Spectral, Medical device

where he will discuss the rationale for polymyxin B hemoperfusion and other therapies in sepsis on Wednesday, June 15, 2022, at 10:40 AM CET.

Key Points: 
  • where he will discuss the rationale for polymyxin B hemoperfusion and other therapies in sepsis on Wednesday, June 15, 2022, at 10:40 AM CET.
  • Dr. Kellum has been invited to participate in the following featured panels:
    Dr. Kellum will discuss Endotoxemia and Endotoxic Shock and why we should care on Tuesday, June 14, 2022, at 6:30 AM Eastern Time.
  • Dr. Kellum will discuss availability of new tools for decision making on Thursday, June 16, 2022, at 7:15 AM Eastern Time.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).

Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

Retrieved on: 
Tuesday, June 14, 2022
Science, Â, Renal replacement therapy, Hospital, Adult, Time, Company, AKI, KBT, Veni, vidi, vici, Overload, Forward-looking statement, CEO, Volume overload, Hypervolemia, NIH, Nasdaq, CRRT, Acute kidney injury, Health, National Association Medical Staff Services, FDA, Growth, National, Patient, GLOBE, Disease, Mortality, Technology, Private Securities Litigation Reform Act, COVID-19, Jean-Louis Vincent, Journal of Cardiac Failure, SEC, Physician, Diuretic, Medicine, Pharmaceutical industry

The company today announced its Aquadex SmartFlow system is now available at two new pediatric hospitals in Florida and Arkansas.

Key Points: 
  • The company today announced its Aquadex SmartFlow system is now available at two new pediatric hospitals in Florida and Arkansas.
  • Nuwellis therapy meets an unmet need in pediatric patients, and the benefit of the clinically-proven5 technology can be demonstrated through its recent expansion to health centers in Florida and Arkansas.
  • In addition to bringing its existing technology to new pediatric health centers, Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children.
  • Were immensely grateful to the NIH, KBT, and our pediatric nephrologist medical advisors in supporting the development of our pediatric CRRT device.

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Retrieved on: 
Tuesday, June 7, 2022
Kidney, Glomerular filtration rate, Vaccination, Infection, Holm–Bonferroni method, Macrophage, Degenerative disease, EGFR, Company, Death, ATC, Research, NK, HLA, Standard of care, Transplant, Security (finance), BMI, Investor, U.S. Securities and Exchange Commission, Medicine, Nasdaq, Acute kidney injury, Therapy, ID, Medical record, GLOBE, Patient, COVID-19, Northwestern University, Risk, Private Securities Litigation Reform Act, Mouse, Incidence, Immunosuppression, SOC, Bone marrow, Safety, Pharmaceutical industry, Vaccine, Talari Networks

Real-world data comparison of matched controls to Phase 2 treated patients.

Key Points: 
  • Real-world data comparison of matched controls to Phase 2 treated patients.
  • In an oral presentation at the 2022 ATC meeting, Talaris provided an update on the continued long-term follow-up of patients in its Phase 2 LDKT study.
  • ET to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients, pending receipt of data from all participating sites.
  • Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Unicycive to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Monday, June 6, 2022
Conference, Biotechnology, JMP, Kidney, Nasdaq, Acute kidney injury, Therapy, Patient, GLOBE, Kidney disease, Hyperphosphatemia, LOS, Pharmaceutical industry

LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will participate in the JMP Securities Life Sciences Conference taking place June 15-16, 2022 in New York as follows:

Key Points: 
  • LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will participate in the JMP Securities Life Sciences Conference taking place June 15-16, 2022 in New York as follows:
    To schedule a one-on-one meeting with Unicycive, please contact your JMP Securities representative.
  • For questions or further information about Unicycive, please contact Anne Marie Fields of Stern IR at 212-362-1200 or submit your request to [email protected] .
  • Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Retrieved on: 
Thursday, June 2, 2022
Osteoporosis, Absorption, Company, SHPT, Biotechnology, Bone pain, Food, Gastrointestinal tract, Renal osteodystrophy, Artery, Dialysis, Kidney, Hyperphosphatemia, Nasdaq, Chronic kidney disease, Acute kidney injury, Therapy, FDA, Cardiovascular disease, Patient, GLOBE, Pharmacotherapy, Mortality, Risk, Diabetes, Trial of the century, Fracture, Compliance, Kidney disease, Atherosclerosis, Clinical trial, LOS, CKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bone disease, Hypertension, ESRD, Pharmaceutical industry, Lanthanum carbonate, Rastogi

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb (lanthanum dioxycarbonate.)

Key Points: 
  • LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb (lanthanum dioxycarbonate.)
  • Renazorb is a novel phosphate binding agent utilizing proprietary nanoparticle technology that is being developed by Unicycive for the treatment of hyperphosphatemia.
  • The study is a randomized, open label, two-way crossover BE study to establish pharmacodynamic bioequivalence between Renazorb and Fosrenol.
  • The Renazorb program is supported by a previously completed clinical trial that studied Renazorb in 32 healthy volunteers.

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

Retrieved on: 
Saturday, June 4, 2022
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Subclinical infection, Constipation, Infection, Pneumonia, Head, TNBC, Endometrial cancer, Hair, Nausea, Anemia, Fatigue, Abdominal pain, HIV disease progression rates, Progression-free survival, Science, Nasdaq, SAR, U.S. Securities and Exchange Commission, Acute kidney injury, Appetite, Neutropenia, Red blood cell, Patient, Private Securities Litigation Reform Act, Risk, Sepsis, Incidence, Lymphocyte, SCLC, Neutrophil, Gilead Sciences, Twitter, Vomiting, File, HIV, Diarrhea, Urinary tract infection, Medicine, PFS, Rash, UGT1A1, NSCLC, TPC, Febrile neutropenia, Death, Cancer, MUC, Pharmaceutical industry, Sacituzumab govitecan

In TROPiCS-02, we enrolled heavily pre-treated patients with metastatic breast cancer who had disease progression following multiple lines of chemotherapy.

Key Points: 
  • In TROPiCS-02, we enrolled heavily pre-treated patients with metastatic breast cancer who had disease progression following multiple lines of chemotherapy.
  • Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer.
  • Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%.
  • As patients with HR+/HER2- metastatic breast cancer become resistant to endocrine-based therapy, their primary treatment option is limited to single-agent chemotherapy.

Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, People, Janus, Human, Adult, Pneumonia, HSCT, COVID, Nausea, Anemia, Abdominal pain, RA, Food, Psoriatic arthritis, Standard of care, Degenerative disease, Cancer, Bristol Myers Squibb, Hypermagnesemia, NIH, Upper respiratory tract infection, CD4, Lymphoma, Acute kidney injury, TNF, Hypoxia, BMY, Hematopoietic stem cell transplantation, JAK, National, Patient, Cough, Mortality, Risk, Host, NYSE, COVID-19, Lung cancer, MD, Hypertension, Diarrhea, Infection, Common, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Headache, Nosebleed, CMV, Safety, Methotrexate, Pharmaceutical industry, Vaccine, Fever, Vaccine, Abatacept

Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.

Key Points: 
  • Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.
  • Hypersensitivity: There were 2 cases (
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
  • In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

InsightRX Helps Boone County Hospital Improve Patient Safety with Precision Dosing

Retrieved on: 
Wednesday, June 1, 2022
Magnetic resonance, Precision medicine, Goal, Vancomycin, Time, AKI, Journal, Pharmacy, Infection, Akis, Doctor of Philosophy, CEO, Software, Partnership, FAO Major Fishing Areas, Physician, Acute kidney injury, Tinnitus, Method, Machine learning, Patient, Hospital, Risk, Boone Hospital Center, Review, Technology, Antimicrobial stewardship, SAN, CMS, Efficiency, Journal of Pharmacy Practice and Research, Patient safety, Pharmaceutical industry, Medical device

SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Today InsightRX, a healthcare technology company which provides cloud-based precision dosing support to guide treatment decisions, announced that Boone County Hospital, a 25-bed critical access hospital in Iowa, implemented model-informed precision dosing via its point-of-care InsightRX Nova platform to reduce acute kidney infections resulting in zero nephrotoxicity events. The hospital has also improved the number of patients achieving the desired therapeutic range for their antibiotic regimen by 27% in one year. 

Key Points: 
  • SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Today InsightRX , a healthcare technology company which provides cloud-based precision dosing support to guide treatment decisions, announced that Boone County Hospital, a 25-bed critical access hospital in Iowa, implemented model-informed precision dosing via its point-of-care InsightRX Nova platform to reduce acute kidney infections resulting in zero nephrotoxicity events.
  • In May 2019, Boone County Hospital implemented InsightRX Nova, a precision dosing platform that uses pharmacokinetic model-informed Bayesian forecasting, to standardize its therapeutic drug monitoring for four key antibiotics, including vancomycin.
  • While many smaller hospitals assumed they would be unable to meet the new standard of treatment, Boone Hospital was already practicing next-generation precision dosing with its patients.
  • "Boone County Hospital is a great example of how even smaller, more rural facilities can leverage model-informed precision dosing to have a significant impact on patient safety," said Sirj Goswami, PhD, co-founder and CEO of InsightRX.

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Retrieved on: 
Tuesday, May 24, 2022
People, CLR, Severe acute respiratory syndrome coronavirus 2, Platelet, Risk, Death, Shock, Organ dysfunction, Autoimmune hemolytic anemia, Thermoregulation, Waiha, Patient, Common, Antibody, Macrovascular disease, GUD, AIHA, Endothelial dysfunction, Therapy, Macrophage, Nature, COVID-19, Jean-Louis Vincent, TSX, Bruise, Intention, Infection, Partnership, Bleeding, ITP, SYK, Splenectomy, Pathology, Neutrophil extracellular traps, Acute kidney injury, Neutrophil, NETS, Monocyte, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), Immune system, Steroid, Knight Therapeutics, Fostamatinib, CEO, Annual report, GLOBE, Pharmaceutical industry, Vaccine, Generic drug, Rigel, Uniting Medically Supervised Injecting Centre, Knight

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Key Points: 
  • MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.
  • We are excited to be working with Rigel to provide access to an innovative, first-in-class treatment option to patients across Latin America with chronic ITP.
  • TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.
    Investor Contact for Knight Therapeutics Inc.:

Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022

Retrieved on: 
Monday, May 16, 2022
Physician, Chronic kidney disease, CAD, Risk, CKD, Philips, Fluoroscopy, AEX, Agent handling, ULC, Canton, MD, Doctor of Philosophy, CT pulmonary angiogram, PCI, PHG, UCL, Patient, Catheter, Solution, Quality of life, Injection, FFR, Contrast-induced nephropathy, Interventional cardiology, Percutaneous coronary intervention, Increment, AKI, Toxicity, AJC, Safety, Artery, Stenosis, IVUS, Prognosis, Frailty, CET, CIN, Coronary artery disease, Pilot in command, NYSE, Multicenter Automatic Defibrillator Implantation Trial, Acute kidney injury, Medical imaging, Hospital

Philips ULC-PCI solutions co-register instantaneous blood flow measurements and/or intravascular ultrasound (IVUS) images onto real-time fluoroscopy to help interventionists diagnose, decide, guide, treat and confirm the success of PCI, with the potential to limit the use of iodinated contrast media.

Key Points: 
  • Philips ULC-PCI solutions co-register instantaneous blood flow measurements and/or intravascular ultrasound (IVUS) images onto real-time fluoroscopy to help interventionists diagnose, decide, guide, treat and confirm the success of PCI, with the potential to limit the use of iodinated contrast media.
  • Seamlessly integrating into Philips Image Guided Therapy System - Azurion - the companys unique ULC-PCI solutions provide physicians with tools to help reduce the use of contrast media throughout PCI procedures.
  • "As a result, more complex patients can now undergo PCI, including those with advanced age and frailty, chronic renal failure, and associated heart conditions.
  • In many of these patients, where the injection of radiological contrast used to guide the PCI can have deleterious effects, technologies developed by Philips that enable physicians to dramatically decrease contrast administration during the procedure is contributing to both the safety and quality of PCI.